uniQure stock falls after FDA feedback on gene therapy application
uniQure N.V. (QURE) stock fell following feedback from the U.S. FDA during a recent pre-Biologics License Application (BLA) meeting about AMT-130, a gene therapy being investigated for Huntington’s disease. The discussions indicated that the FDA may...
Seeking Alpha